Dr. William Holderman
Claim this profileWashington Gastroenterology, PLLC
Affiliated Hospitals
Washington Gastroenterology PLLC
Digestive Health Specialists
Clinical Trials William Holderman is currently running
Vedolizumab + Adalimumab/Ustekinumab
for Crohn's Disease
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A. Each participant will be followed up for at least 26 weeks after the last dose of treatment.
Recruiting
3 awards
Phase 4
10 criteria
Vedolizumab + Tofacitinib
for Ulcerative Colitis
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
Recruiting
3 awards
Phase 4
7 criteria
More about William Holderman
Clinical Trial Related
6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments William Holderman has experience with
- Mirikizumab
- Vedolizumab
- Tofacitinib
- Adalimumab
- Ustekinumab
- IMU-838
Breakdown of trials William Holderman has run
Ulcerative Colitis
Colitis
Crohn's Disease
Inflammatory Bowel Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William Holderman specialize in?
William Holderman focuses on Ulcerative Colitis and Colitis. In particular, much of their work with Ulcerative Colitis has involved treating patients, or patients who are undergoing treatment.
Is William Holderman currently recruiting for clinical trials?
Yes, William Holderman is currently recruiting for 2 clinical trials in Tacoma Washington. If you're interested in participating, you should apply.
Are there any treatments that William Holderman has studied deeply?
Yes, William Holderman has studied treatments such as Mirikizumab, Vedolizumab, Tofacitinib.
What is the best way to schedule an appointment with William Holderman?
Apply for one of the trials that William Holderman is conducting.
What is the office address of William Holderman?
The office of William Holderman is located at: Washington Gastroenterology, PLLC, Tacoma, Washington 98405 United States. This is the address for their practice at the Washington Gastroenterology, PLLC.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.